Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000097:blood / Q000150:complications; D005260:Female; D015248:Gemfibrozil; D006801:Humans; D006937:Hypercholesterolemia / Q000178:diet therapy / Q000188:drug therapy / Q000209:etiology; D006949:Hyperlipidemias / Q000628:therapy*; D006953:Hyperlipoproteinemia Type IV / Q000178:diet therapy / Q000209:etiology; D006951:Hyperlipoproteinemias / Q000188:drug therapy; D007774:Lactation; D008074:Lipoproteins / Q000097:blood*; D008148:Lovastatin / Q000031:analogs & derivatives; D009281:Naphthalenes / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use; D010421:Pentanoic Acids / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000178:diet therapy; D011341:Probucol / Q000627:therapeutic use; D013631:Tangier Disease / Q000097:blood; D014280:Triglycerides / Q000097:blood
D008074:Lipoproteins; D009281:Naphthalenes; D010421:Pentanoic Acids; D014280:Triglycerides; C012258:mevastatin; D009525:Niacin; D002784:Cholesterol; D008148:Lovastatin; D002994:Clofibrate; D011341:Probucol; D015248:Gemfibrozil